Recent Updates
Recently added Catalysts
PHGE Positive Sentiment

BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023

Wednesday, August 2, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BiomX Inc. will host a conference call and live webcast on August 9, 2023, at 8:00 a.m. ET to report its second quarter financial results and provide business updates. This event aims to engage with investors and provide insights into the company's progress with its phage therapies targeting specific pathogenic bacteria. Interested parties can participate in the call or access the webcast through BiomX's website.
Price reaction · baseline $81.244 (2023-08-01 close) · hit after-hours · clean, no other PHGE news in the window
day 0 close
-2.1%
day 1
-2.2%
day 3
-0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • BiomX is advancing novel therapies targeting pathogenic bacteria.
  • The company is preparing to share updates on financial results.
  • The conference call is an opportunity for investor engagement.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+190%
120-day peak, hindsight
Typical move
13.4%
average across 4 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
BX002-A
Phase 1 · Healthy Volunteers

Full Press Release Details

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, August 9th, 2023, at 8:00 a.m. ET, to report second quarter 2023 financial results and provide business updates.
To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.
BiomX is a clinical-stage company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.biomx.com.
Corporate Project Manager

Frequently Asked Questions

What is BiomX Inc. known for?

BiomX Inc. develops natural and engineered phage therapies to combat specific pathogenic bacteria.

When is BiomX's conference call scheduled?

The conference call is set for August 9th, 2023, at 8:00 a.m. ET.

How can I join the BiomX conference call?

Participants can call 1-877-407-0724 for the U.S. or 1-201-389-0898 internationally.

Where can I find BiomX's webcast?

The live and archived webcast will be available in the Investors section of BiomX's website.

What type of diseases does BiomX aim to treat?

BiomX focuses on chronic diseases by targeting bacteria with phage therapies.

ShareAdd on Google
Tags: PHGE Viatris Investor Conferences Healthcare BiomX financial results conference call phage therapies
Last updated: Aug 2, 2023

Biotech snapshot

Cash runway
$1M liquidity · $0M/mo burn
~1 mo
High dilution risk
Lead asset
BX002-APhase 1
Healthy Volunteers →

Catalyst track record

+190%
best trade around PHGE's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PHGE.

See every catalyst's timing & PoA →